MSD Korea Announces Approval of Keytruda for First-Line Treatment of HER2-Positive Gastric Cancer
MSD Korea held a press conference on the 16th to commemorate the domestic approval of Keytruda (ingredient pembrolizumab) for the first-line treatment indication for HER2-positive advanced gastric cancer or gastroesophageal junction (GEJ) adenocarcinoma. / Photo = Reporter Hwang Jae-seon Keytruda combination therapy was introduced as a new treatment option that demonstrated clinical benefits beyond the […]
